Real-world Assessment of 2,879 COVID-19 Patients Treated with Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study
Cooper et al.
, Real-world Assessment of 2,879 COVID-19 Patients Treated with Monoclonal Antibody Therapy: A Propensity..
, Open Forum Infectious Diseases, doi:10.1093/ofid/ofab512
Retrospective 2,879 patients and matched controls in the USA, showing significantly lower mortality and hospitalization with bamlanivimab, bamlanivimab/etesevimab, and casirivimab/imdevimab. There was significantly lower hospitalization with casirivimab/imdevimab compared to bamlanivimab or bamlanivimab/etesevimab. PSM and multivariate analysis is only provided for all treatments combined.Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, VanBlargan].
This study is excluded in the after exclusion results of meta
unadjusted results with no group details.
risk of death, 45.3% lower, RR 0.55, p = 1.00, treatment 1 of 473 (0.2%), control 33 of 8,534 (0.4%), NNT 571, unadjusted, bamlanivimab-etesevimab.
risk of ICU admission, 57.5% lower, RR 0.42, p = 0.33, treatment 2 of 473 (0.4%), control 85 of 8,534 (1.0%), NNT 174, unadjusted, bamlanivimab-etesevimab.
risk of hospitalization, 5.0% lower, RR 0.95, p = 0.86, treatment 37 of 473 (7.8%), control 703 of 8,534 (8.2%), NNT 241, unadjusted, bamlanivimab-etesevimab, primary outcome.
risk of death, 17.2% higher, RR 1.17, p = 0.59, treatment 11 of 2,427 (0.5%), control 33 of 8,534 (0.4%), unadjusted, bamlanivimab.
risk of ICU admission, 9.0% lower, RR 0.91, p = 0.81, treatment 22 of 2,427 (0.9%), control 85 of 8,534 (1.0%), NNT 1117, unadjusted, bamlanivimab.
risk of hospitalization, 28.0% lower, RR 0.72, p < 0.001, treatment 144 of 2,427 (5.9%), control 703 of 8,534 (8.2%), NNT 43, unadjusted, bamlanivimab.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cooper et al., 8 Oct 2021, retrospective, USA, peer-reviewed, 9 authors.
Abstract: Real-world Assessment of 2,879 COVID-19 Patients Treated with Monoclonal
Antibody Therapy: A Propensity Score-Matched Cohort Study
Nguyen3, James M. Musser2,3, Howard J. Huang4, Michael G. Liebl1,*
Department of Pharmacy, Houston Methodist Hospital, Houston, Texas, USA
Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas,
Center for Molecular and Translational Human Infectious Diseases Research, Houston Methodist
Research Institute, Houston, Texas, USA
Houston, TX, USA
Division of Pulmonology, Pulmonary, Critical Care & Sleep Medicine, Houston Methodist Hospital,
Michael G. Liebl, PharmD, BCPS; 7550 Greenbriar Dr. RB6-126, Houston, TX, USA 77030; Ph:
346.356.1757; Email: email@example.com
Alternate corresponding author:
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious
Diseases Society of America.
This is an Open Access article distributed under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-ncnd/4.0/), which permits non-commercial reproduction and distribution of the work, in any
medium, provided the original work is not altered or transformed in any way, and that the
work is properly cited. For commercial re-use, please contact firstname.lastname@example.org
Megan H. Cooper1, Paul A. Christensen2, Eric Salazar2, Katherine K. Perez1,2, Edward A. Graviss3, Duc
Megan H. Cooper, PharmD; 6565 Fannin St, DB1-09, Houston, TX, USA 77030; Ph: 713-441-7055;
Summary: We assessed the outcomes of 2,879 SARS-CoV-2-positive patients transfused with one of
cohort. We found that administration of mAbs significantly reduced 28-day hospitalizations and
Background: SARS-CoV-2 continues to spread globally and cause significant morbidity and mortality.
Anti-spike protein monoclonal antibody (mAb) therapy has been shown to prevent progression to
severe COVID-19 disease. The objective of this study was to report the outcomes of high-risk, SARS-
CoV-2-positive patients infused with one of the three mAb available through FDA emergency use
Methods: A total of 4,328 SARS-CoV-2-positive patients that satisfied EUA criteria for eligibility for
receiving mAb therapy were infused with bamlanivimab or combination therapies bamlanivimab-
etesevimab or casirivimab-imdevimab from November 22, 2020, to May 31, 2021, at six infusion
clinics and multiple emergency departments within the eight Houston Methodist Hospitals in
Houston, Texas. The primary outcome of hospital admission within 14- and 28-days post-infusion
was assessed relative to a propensity-score matched cohort, matched based on age, race/ethnicity,
median income by zip code, body mass index, comorbidities, and positive PCR date. Secondary
outcomes included ICU admission and mortality.
Results: A total of 2,879 infused patients and matched controls were included in the analysis,
including 1,718 patients infused with bamlanivimab, 346 patients infused with bamlanivimab-
three available monoclonal antibody..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.